Evidence map›Paper›PMID 26231668›Full record

ArticleClinical & experimental metastasis2015

Expression array analysis of the hepatocyte growth factor invasive program.

Fabiola Cecchi, Chih-Jian Lih, Young H Lee, William Walsh, Daniel C Rabe, Paul M Williams, Donald P Bottaro

Open access · greenAbstract read
In one paragraph

Article in Clinical & experimental metastasis, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Fabiola CecchiUrologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892-1501, USA.
Chih-Jian LihMolecular Characterization and Clinical Assay Development Laboratory, Leidos Biomedical Research, Inc. and Frederick National Laboratory for Cancer Research, Frederick, MD, 21702-1201, USA.
Young H LeeUrologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892-1501, USA.
William WalshMolecular Characterization and Clinical Assay Development Laboratory, Leidos Biomedical Research, Inc. and Frederick National Laboratory for Cancer Research, Frederick, MD, 21702-1201, USA.
Daniel C RabeUrologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892-1501, USA.
Paul M WilliamsMolecular Characterization and Clinical Assay Development Laboratory, Leidos Biomedical Research, Inc. and Frederick National Laboratory for Cancer Research, Frederick, MD, 21702-1201, USA.
Donald P BottaroUrologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892-1501, USA. don.bottaro@nih.gov.ORCID http://orcid.org/0000-0002-5057-5334
National Institutes of Health · USLeidos (United States) · US

Funding

Oncogenic Met Signaling in Urologic MalignanciesZIABC011124 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI BOTTARO, DONALD · 2009 to 2021
$5.8M
Oncogenic Met Signaling in Urologic MalignanciesZ01BC011124 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI BOTTARO, DONALD · 2008 to 2008
$242k
Identification of HIF-Regulated Oncogenic Mediators in Renal Cell CarcinomaZ01BC011095 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI BOTTARO, DONALD · 2008 to 2008
$97k
Intramural NIH HHS Z01 BC011095Intramural NIH HHS Z01 BC011124
6 · The paper itself

Abstract

Signaling by human hepatocyte growth factor (hHGF) via its cell surface receptor (MET) drives mitogenesis, motogenesis and morphogenesis in a wide spectrum of target cell types and embryologic, developmental and homeostatic contexts. Oncogenic pathway activation also contributes to tumorigenesis and cancer progression, including tumor angiogenesis and metastasis, in several prevalent malignancies. The HGF gene encodes full-length hHGF and two truncated isoforms known as NK1 and NK2. NK1 induces all three HGF activities at modestly reduced potency, whereas NK2 stimulates only motogenesis and enhances HGF-driven tumor metastasis in transgenic mice. Prior studies have shown that mouse HGF (mHGF) also binds with high affinity to human MET. Here we show that, like NK2, mHGF stimulates cell motility, invasion and spontaneous metastasis of PC3M human prostate adenocarcinoma cells in mice through human MET. To identify target genes and signaling pathways associated with motogenic and metastatic HGF signaling, i.e., the HGF invasive program, gene expression profiling was performed using PC3M cells treated with hHGF, NK2 or mHGF. Results obtained using Ingenuity Pathway Analysis software showed significant overlap with networks and pathways involved in cell movement and metastasis. Interrogating The Cancer Genome Atlas project also identified a subset of 23 gene expression changes in PC3M with a strong tendency for co-occurrence in prostate cancer patients that were associated with significantly decreased disease-free survival.

Indexed as

AnimalsCell Line, TumorGene Expression ProfilingHepatocyte Growth FactorHeterograftsHumansMaleMiceNeoplasm InvasivenessOligonucleotide Array Sequence AnalysisProstatic NeoplasmsProtein IsoformsProto-Oncogene Proteins c-metSignal TransductionHepatocyte Growth FactorProtein IsoformsProto-Oncogene Proteins c-metCell migrationHepatocyte growth factorMET receptor tyrosine kinaseProstate cancerSignal transductionTumor metastasis

Identifiers

PMID26231668
PMCPMC7709798
OpenAlexW1003290934

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.